IMMVF (Immunovia AB) Moat Score: 0/10 (As of Jul. 02, 2026)


IMMVF Immunovia AB IMMVF
44 GF Score
Price $0.02
GF Value $0.01
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Moat Score?

Immunovia AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Immunovia AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Immunovia AB might have No Moat - No discernible moat.

Immunovia AB  (OTCPK:IMMVF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Immunovia AB Moat Score Related Terms

IMMVF
44GF Score
Immunovia AB IMMVF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunovia AB (IMMVF) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.

Key valuation signals for IMMVF:

  • Moat Score: 0
  • GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges IMMNOV:Sweden0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
44GF Score

Get the complete analysis for IMMVF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.01
GF Value